PMID- 12105753
OWN - NLM
STAT- MEDLINE
DCOM- 20020726
LR  - 20041117
IS  - 0341-2040 (Print)
IS  - 0341-2040 (Linking)
VI  - 180
IP  - 1
DP  - 2002
TI  - Additive effect of Interleukin-12 and Interleukin-18 on the T-helper cell pathway 
      of malignant pleural effusion.
PG  - 15-24
AB  - Interleukin-18 (IL-18) is a novel cytokine with interferon-gamma 
      (IFN-gamma)-inducing activity, thus favoring the T-helper type 1 (Th-1) pathway. 
      The present study attempts to define the role of IL-18 on the functions of 
      lymphocytes isolated from malignant pleural effusions (EAL, effusion-associated 
      lymphocytes). EAL from 10 patients with malignant pleural effusion were incubated 
      with IL-2, IL-12, or IL-18 with/without a alpha CD3 antibody. ELISA, 
      proliferation, and cytotoxicity assays were performed. IL-18 alone was found to 
      have no significant effect on EAL in terms of cytokine production, lymphocyte 
      proliferation, or cytotoxicity against tumor targets. IL-18 also had no 
      significant additive or synergistic effect on IL-2, IL-12, or alpha CD3 
      co-cultured EAL. However, when IL-18 was used with IL-12, the highest 
      IFN-gamma/IL-10 ratio was derived, suggesting that these two cytokines had an 
      additive effect in leading EAL from the Th-2 to the Th-1 pathway. Furthermore, 1 
      of 5 patients' EAL had its strongest cytolytic activity against an autologous 
      tumor when the EAL was cultured with IL-2 plus IL-18, as compared with the other 
      4 patients whose EAL cytolytic activity against autologous tumor was highest when 
      using IL-2 plus alpha CD3. These findings suggest that IL-18 alone did not have a 
      significant effect on EAL, and that IL-18 did not enhance alpha CD3's activity on 
      EAL. However, its additive effect with IL-12 in the Th-1 pathway and with IL-2 in 
      its cytolytic activity against an autologous tumor deserve further studies.
FAU - Yao, N S
AU  - Yao NS
AD  - Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan, R.O.C.
FAU - Chen, Y M
AU  - Chen YM
FAU - Perng, R P
AU  - Perng RP
FAU - Whang-Peng, J
AU  - Whang-Peng J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lung
JT  - Lung
JID - 7701875
RN  - 0 (Interleukin-18)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Adenocarcinoma/complications
MH  - Aged
MH  - Female
MH  - Humans
MH  - Interleukin-12/*immunology
MH  - Interleukin-18/*immunology
MH  - Lung Neoplasms/complications
MH  - Male
MH  - Pleural Effusion, Malignant/immunology/*pathology
MH  - T-Lymphocytes, Helper-Inducer/*immunology
EDAT- 2002/07/10 10:00
MHDA- 2002/07/27 10:01
CRDT- 2002/07/10 10:00
PHST- 2002/01/08 00:00 [accepted]
PHST- 2002/07/10 10:00 [pubmed]
PHST- 2002/07/27 10:01 [medline]
PHST- 2002/07/10 10:00 [entrez]
AID - 10.1007/s004080000077 [doi]
PST - ppublish
SO  - Lung. 2002;180(1):15-24. doi: 10.1007/s004080000077.